Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Chronic Kidney Disease (CKD) Patients
CTR20190756Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of empagliflozin in chronic kidney disease (CKD), sponsored by Boehringer Ingelheim. Started Jul 2019; status: completed.
02
Drugs
empagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20190756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190756.